Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
MAFb
OS
PFS
POMP
bortezomib
cMAF
multiple myeloma
prognosis
survival
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
28 Oct 2021
28 Oct 2021
Historique:
received:
12
08
2021
revised:
21
10
2021
accepted:
26
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
While multiple myeloma (MM) treatment with proteasome inhibitors and other agents yields encouraging results, primary and secondary resistance remains an emerging problem. An important factor in such treatment resistance is the overexpression of several proteins. The present study comprehensively evaluates the expression of POMP, PSMB5, NRF2, XBP1, cMAF and MAFb proteins in plasma cells isolated from the bone marrow of 39 MM patients treated with bortezomib-based regimens using an enzyme-linked immunosorbent assay (ELISA). The proteins were selected on the basis of previous laboratory and clinical studies in bortezomib-treated MM patients. It was found that the expression of the investigated proteins did not significantly differ between bortezomib-sensitive and bortezomib-refractory patients. However, the expression of some proteins correlated with overall survival (OS); this was significantly shorter in patients with higher POMP expression (HR 2.8, 95% CI: 1.1-7.0,
Identifiants
pubmed: 34768548
pii: jcm10215028
doi: 10.3390/jcm10215028
pmc: PMC8584776
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Narodowe Centrum Nauki (NCN - National Science Centre
ID : 2016/23/B/NZ5/02529).
Références
Leukemia. 2015 Mar;29(3):715-26
pubmed: 25179733
J Pharmacol Toxicol Methods. 2017 Nov;88(Pt 1):1-6
pubmed: 28465161
Curr Cancer Drug Targets. 2011 Mar;11(3):239-53
pubmed: 21247388
Leukemia. 2010 Aug;24(8):1506-12
pubmed: 20555361
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9926-30
pubmed: 7937919
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Leuk Res. 2012 Feb;36(2):212-8
pubmed: 21978467
Blood. 2008 Sep 15;112(6):2489-99
pubmed: 18565852
Leukemia. 2008 Feb;22(2):231-9
pubmed: 17972944
Br J Haematol. 2015 Jul;170(1):66-79
pubmed: 25824111
Gene. 2016 Jul 25;586(2):197-205
pubmed: 27058431
Cancers (Basel). 2021 Feb 25;13(5):
pubmed: 33668794
Cancer Treat Rev. 2018 Nov;70:199-208
pubmed: 30245231
Cancer Metastasis Rev. 2017 Dec;36(4):561-584
pubmed: 29196868
Mol Cancer Res. 2020 Oct;18(10):1453-1464
pubmed: 32561655
Cancer Lett. 2018 Jan 1;412:37-45
pubmed: 29031566
Cell Death Dis. 2017 Sep 21;8(9):e3058
pubmed: 28933784
Drugs R D. 2019 Jun;19(2):73-92
pubmed: 30993606
J Immunol Methods. 2017 Dec;451:90-99
pubmed: 28943257
Clin Proteomics. 2019 Apr 23;16:17
pubmed: 31043929
J Biol Chem. 2015 Dec 11;290(50):29854-68
pubmed: 26483548
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
N Engl J Med. 2008 Aug 28;359(9):906-17
pubmed: 18753647
Dtsch Arztebl Int. 2016 Jul 11;113(27-28):470-6
pubmed: 27476706
Oncotarget. 2016 Aug 30;7(35):56726-56736
pubmed: 27527861
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cancers (Basel). 2021 Apr 02;13(7):
pubmed: 33918370
BMC Cancer. 2018 Jul 6;18(1):724
pubmed: 29980194
Nat Rev Cancer. 2008 Sep;8(9):683-93
pubmed: 19143053
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Biomed Pharmacother. 2020 Jul;127:110069
pubmed: 32294597
Front Oncol. 2020 Jan 22;9:1530
pubmed: 32039016
Acta Pharmacol Sin. 2019 Dec;40(12):1568-1577
pubmed: 31197245
Clin Chim Acta. 2020 Apr;503:45-53
pubmed: 31901479
Mediators Inflamm. 2020 Jun 6;2020:1835836
pubmed: 32587468
Biochim Biophys Acta. 2012 Oct;1823(10):1841-6
pubmed: 22721719
Cancers (Basel). 2020 Sep 09;12(9):
pubmed: 32916955
J Clin Pathol. 2016 Feb;69(2):97-101
pubmed: 26598624
Jpn J Clin Oncol. 2018 Sep 1;48(9):785-793
pubmed: 30102324
Proteomics. 2011 Apr;11(8):1391-402
pubmed: 21365752